Regulatory Approval To Start PBT2 Phase IIa Clinical Trial In Alzheimer's Disease Patients

Regulatory Approval To Start PBT2 Phase IIa Clinical Trial In Alzheimer's Disease Patients: "Prana Biotechnology Limited (Nasdaq: PRAN; ASX: PBT), today announced that it has received regulatory approval from Sweden's Medical Products Agency (MPA) to start a Phase IIa clinical trial of its proprietary lead compound, PBT2, in patients with early Alzheimer's disease. The trial will be conducted in seven centres in Sweden."